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1. INTRODUCTION {#hec3787-sec-0002}
===============

Recent developments in social surveys include the integration of biomarkers and self‐reported health measures. Biomarkers are objectively measured indicators of normal biological or pathogenic processes and, as such, offer at least two key advances over self‐report health. First, biomarkers are not subject to reporting bias; given evidence for socio‐economic‐related reporting bias in health, biomarkers offer a significant advantage in socioeconomic inequalities research (Bago d\'Uva, O\'Donnell, & van Doorslaer, [2008](#hec3787-bib-0001){ref-type="ref"}; Carrieri & Jones, [2017](#hec3787-bib-0002){ref-type="ref"}). Second, biomarkers can contribute to our understanding of the underlying biological factors through which socioeconomic conditions get "under the skin" (e.g., thought stress‐related physiological responses) and the role of socioeconomic exposures at earlier pre‐symptomatic health states (Davillas, Benzeval, & Kumari, [2017](#hec3787-bib-0003){ref-type="ref"}; Jürges, Kruk, & Reinhold, [2013](#hec3787-bib-0006){ref-type="ref"}).

A growing literature analyses the effect of socioeconomic position on the conditional mean of biomarkers (e.g., Davillas et al., [2017](#hec3787-bib-0003){ref-type="ref"}, Jürges et al., [2013](#hec3787-bib-0006){ref-type="ref"}). However, biomarkers create several statistical modeling challenges as they often have skewed distributions with heavy tails (Jones, [2017](#hec3787-bib-0004){ref-type="ref"}). Furthermore, errors are likely to be heteroskedastic and responses to covariates may be nonlinear. Existing studies have estimated linear regression models using ordinary least squares (OLS) on raw or log‐transformed biomarkers (Jürges et al., [2013](#hec3787-bib-0006){ref-type="ref"}) and alternative inherently nonlinear specifications, such as the generalized linear models (Davillas et al., [2017](#hec3787-bib-0003){ref-type="ref"}). Although OLS on log rather than on levels might improve performance by reducing skewness, re‐transformation to the raw scale---as health policymakers require---is highly challenging, requiring knowledge of the degree and form of heteroscedasticity (Jones, Lomas, & Rice, [2014](#hec3787-bib-0005){ref-type="ref"}). Although the generalized linear model family deals with heteroskedasticity, it fails to explicitly account for skewness and kurtosis, imposing potential bias and efficiency losses (Jones et al., [2014](#hec3787-bib-0005){ref-type="ref"}).

Our paper contributes to the literature on modeling biomarkers by comparing the performance of a set of more flexible parametric distributions, the generalized beta of the second kind (GB2), the generalized gamma (GG), and their nine nested and limiting cases; we use nationally representative UK data on commonly used blood‐based biomarkers for inflammation, diabetes, cholesterol, and stress‐related hormones (Carrieri & Jones, [2017](#hec3787-bib-0002){ref-type="ref"}). The GG and GB2 allow for a wide range of skewness and kurtosis to better accommodate the biomarker data generation processes; these distributions have been proposed for fitting heavily skewed outcomes (e.g., health care costs; Jones et al., [2014](#hec3787-bib-0005){ref-type="ref"}), to which biomarkers share similar distributional features. For comparison purposes, linear regression models using OLS are also estimated. Given that different biomarkers exhibit different distributions, identifying GB2 as a discriminatory tool among competing distributions might be useful for health researchers. Going "beyond the mean", we also explore to what extent the GB2 and its nested cases that exerted the best goodness of fit (for each biomarker) regarding the whole distribution also perform well to predict tail probabilities.

2. METHODS {#hec3787-sec-0003}
==========

The three‐parameter GG distribution has been introduced as robust alternative to common estimation techniques for asymmetric data (Manning, Basu, & Mullahy, [2005](#hec3787-bib-0007){ref-type="ref"}). More recently, Jones, Lomas, and Rice ([2014](#hec3787-bib-0005){ref-type="ref"}) have suggested adding further flexibility based on the four‐parameter GB2 distribution. GB2 allows for a wider range of skewness and kurtosis, choosing among its several special or nested cases, whereas GB2\'s extra flexibility may also enhance performance (Jones et al., [2014](#hec3787-bib-0005){ref-type="ref"}).

The GG distribution has a density function and conditional expectation that take the form: $$f\left( {y;\kappa,\mu,\sigma} \right) = \frac{\gamma^{\gamma}}{\sigma y\sqrt{\gamma}\Gamma\left( \gamma \right)}\exp\left( {z\sqrt{\gamma} - u} \right)$$and $$E\left( y \middle| x \right) = \exp\left( {x^{\prime}\beta} \right)\left\lbrack {\kappa^{2\sigma/\kappa}\frac{\Gamma\left( {\frac{1}{\kappa^{2}} + \frac{\sigma}{\kappa}} \right)}{\Gamma\left( \frac{1}{\kappa^{2}} \right)}} \right\rbrack,$$where , , , , and is the gamma function. Parameters and are the shape parameters (Manning et al., [2005](#hec3787-bib-0007){ref-type="ref"}). The GG nests the gamma , Weibull , exponential , and lognormal  distributions.

The four‐parameter GB2 distribution adds further flexibility and has a probability density function and conditional mean of $$f\left( {y;a,b,p,q} \right) = \frac{ay^{\mathit{ap} - 1}}{b^{\mathit{ap}}B\left( {p,q} \right)\left\lbrack {1 + \left( \frac{y}{b} \right)^{a}} \right\rbrack^{({p + q})}}$$and $$E\left( y \middle| x \right) = b\left\lbrack \frac{\Gamma\left( {p + \frac{1}{a}} \right)\Gamma\left( {q - \frac{1}{a}} \right)}{\Gamma\left( p \right)\Gamma\left( q \right)} \right\rbrack,$$where and  are the beta and gamma functions (Jones et al., [2014](#hec3787-bib-0005){ref-type="ref"}). Parameter influences kurtosis and and the skewness of the distribution. We also estimate the nested and limiting cases of GB2: the three‐parameter beta of the second kind (B2) \[, Singh--Maddala (SM) \[, and Dagum \[; the two‐parameter Fisk \[\], and Lomax \]. GG itself is also a limiting case of the GB2, where and (Jones et al., [2014](#hec3787-bib-0005){ref-type="ref"}). We also estimate linear regression models using OLS.

The restrictions imposed by each of the special and limiting cases within the GG and GB2 are evaluated using Wald and likelihood ratio (LR) tests. To assess the comparative performance of beta‐ with gamma‐family distributions (being limited cases and not a linear restriction of a parameter), we compare Akaike (AIC) and Bayesian (BIC) information criteria across all models (Jones et al., [2014](#hec3787-bib-0005){ref-type="ref"}).

3. DATA {#hec3787-sec-0004}
=======

The UK Household Panel Study (UKHLS) is a large, nationally representative UK study. At UKHLS Wave 2, participants from its predecessor, the British Household Panel Survey, were also incorporated. Non‐fasted blood samples were collected, after the UKHLS Wave 2 interview for the original UKHLS respondents and, at Wave 3, for the British Household Panel Survey sample. Pooling biomarker data from UKHLS Waves 2 and 3 (2010--2013) resulted in a potential sample of 13,107 respondents.

Four biomarkers are used. Fibrinogen is an inflammatory biomarker, with higher values linked to cardiovascular morbidity and all‐cause mortality risks (Davillas et al., [2017](#hec3787-bib-0003){ref-type="ref"}). Glycated hemoglobin (HbA1c) is a diagnostic biomarker for diabetes. The ratio of total cholesterol to high‐density lipoprotein cholesterol is used as a marker for fatty substances in the blood. Dehydroepiandrosterone sulfate (DHEAS) is a steroid hormone and one of the mechanisms through which psychosocial stressors might affect health (Vie, Hufthammer, Holmen, Meland, & Breidablik, [2014](#hec3787-bib-0008){ref-type="ref"}). Given our focus on the comparative performance of parametric distributions regarding goodness of fit, rather than explore potential effects from covariates, a parsimonious set of covariates is used: polynomials of age (cubic or quartic depending on the biomarker used), gender, and their interactions to allow for flexible gender effects (Figure [A1](#hec3787-fig-0003){ref-type="fig"}). [^1]

4. RESULTS {#hec3787-sec-0005}
==========

Figure [1](#hec3787-fig-0001){ref-type="fig"} presents the distribution of biomarkers (descriptive statistics in Table [A1](#hec3787-tbl-0003){ref-type="table"}). Fibrinogen has a symmetric distribution but with fat tails (Figure [1](#hec3787-fig-0001){ref-type="fig"}). HbA1c is much more skewed (skewness statistic of 4.2 compared with zero for normal data) with long right‐hand tails and excess kurtosis (31.15 vs. 3 for normal data; Table [A1](#hec3787-tbl-0003){ref-type="table"}). The cholesterol ratio and DHEAS also exhibit long right‐hand tails and high kurtosis.

![Distribution of biomarkers and quantile‐normal (Q‐N) plots. DHEAS: dehydroepiandrosterone sulfate; HbA1c: glycated hemoglobin \[Colour figure can be viewed at <http://wileyonlinelibrary.com>\]](HEC-27-1617-g001){#hec3787-fig-0001}

Table [1](#hec3787-tbl-0001){ref-type="table"} contains restriction tests for the nested and limiting cases within the GG and GB2. Across all biomarkers, we find no evidence in support of any of the special cases within the GG distribution. For fibrinogen, we are unable to reject the null hypothesis of the restriction being valid for the SM model. Our results for HbA1c do not support any of the nested distributions. For the cholesterol ratio, both the LR and Wald tests favor the B2 distribution. Although the Wald test also fails to reject the null hypothesis for SM, this is not confirmed by the LR test; this disparity reflects the wide confidence intervals for GB2\'s  parameter (which include both 1, satisfying the SM restriction, and 0; Table [A2](#hec3787-tbl-0004){ref-type="table"}). Our results for DHEAS favor the SM distribution.

###### 

LR and Wald tests (*p*‐values) for special cases of the GB2 and GG

                   Fibrinogen   HbA1c       Cholesterol ratio   DHEAS                                       
  ---------------- ------------ ----------- ------------------- ------- ----------- ----------- ----------- -----------
  GB2 versus ...                                                                                            
  B2               0.000        0.000       0.000               0.000   **0.247**   **0.193**   0.000       0.000
  SM               **0.208**    **0.236**   0.000               0.000   0.000       0.188       **0.703**   **0.710**
  Dagum            0.004        0.013       0.000               0.000   0.000       0.020       0.000       0.000
  Fisk             0.002        0.000       0.000               0.000   0.000       0.000       0.000       0.000
  Lomax            0.000        0.000       0.000               0.000   0.000       0.000       0.000       0.000
  GG versus ...                                                                                             
  Gamma            0.000        0.024       0.000               0.000   0.000       0.000       0.000       0.000
  Lognormal        0.000        0.000       0.000               0.000   0.000       0.000       0.000       0.000
  Weibull          0.000        0.000       0.000               0.000   0.000       0.000       0.000       0.000
  Exponential      0.000        0.000       0.000               0.000   0.000       0.000       0.000       0.000

*Note*. B2: beta of the second kind; DHEAS: dehydroepiandrosterone sulfate; LR: likelihood ratio; GB2: generalized beta of the second kind; GG: generalized gamma; HbA1c: glycated hemoglobin; SM: Singh--Maddala. For each biomarker, bold *p*‐values highlight those models that we are not able to reject the null hypothesis of restrictions being valid, according to both the LR and Wald tests, compared to the GB2 or GG models.

Table [2](#hec3787-tbl-0002){ref-type="table"} shows that AIC and BIC results are in accordance with the tests of Table [1](#hec3787-tbl-0001){ref-type="table"}. For all biomarkers, linear regressions estimated by OLS perform worse than each of the four‐ and three‐parameter and most of the more parsimonious distributions. For fibrinogen, GB2 and SM perform best according to AIC and BIC criteria, with the latter showing the best performance. GB2 outperforms all the competing distributions regarding HbA1c. Although the B2 and SM distributions exhibit the best performance for the cholesterol ratio and DHEAS, GB2 is ranked the second best.

###### 

AIC and BIC for each model

                Fibrinogen   Hba1c        Cholesterol ratio   DHEAS                                               
  ------------- ------------ ------------ ------------------- ------------ ------------ ------------ ------------ ------------
  GB2           **20,866**   20,948       **72,138**          **72,219**   **39,175**   39,257       **53,800**   53,889
  B2            21,221       21,296       76,134              76,371       **39,173**   **39,249**   53,897       53,979
  SM            **20,865**   **20,939**   72,329              72,404       39,432       39,506       **53,798**   **53,880**
  Dagum         20,872       20,947       72,927              73,001       39,315       39,390       53,855       53,937
  Fisk          20,883       20,950       73,563              73,629       39,482       39,549       54,149       54,223
  Lomax         51,843       51,910       112,182             112,249      59,542       59,624       61,959       62,040
  GG            21,204       21,278       74,986              75,060       39,180       39,270       53,927       54,016
  Lognormal     21,502       21,569       77,305              77,372       39,306       39,373       54,407       54,482
  Gamma         21,219       21,287       79,049              79,116       39,867       39,934       53,942       54,016
  Weibull       22,804       22,871       88,676              88,743       42,443       42,518       54,640       54,715
  Exponential   51,841       51,900       112,180             112,239      59,540       59,615       61,957       62,031
  OLS           21,500       21,558       84,119              84,178       42,875       42,950       58,371       58,446

*Note*. AIC: Akaike information criteria; BIC: Bayesian information criteria; B2: beta of the second kind; DHEAS: dehydroepiandrosterone sulfate; GB2: generalized beta of the second kind; GG: generalized gamma; HbA1c: glycated hemoglobin; OLS: ordinary least squares; SM: Singh--Maddala. For each biomarker, bold values highlight those models that exhibit the best performance according to AIC and BIC.

Figure [2](#hec3787-fig-0002){ref-type="fig"} presents the conditional tail probabilities (at equal to 10th, 25th, 50th, 75th, and 90th quantile) and spike plots of the actual‐fitted difference (bias) for the GB2 distribution, and its nested cases exerted the best performance for each biomarker (Table [2](#hec3787-tbl-0002){ref-type="table"}). Specifically, 20‐quantiles of the fitted values from these models are used to split the sample to calculate within‐quantiles means of actual and predicted probabilities.

![Actual versus fitted tail probabilities. DHEAS: dehydroepiandrosterone sulfate; HbA1c: glycated hemoglobin \[Colour figure can be viewed at <http://wileyonlinelibrary.com>\]](HEC-27-1617-g002){#hec3787-fig-0002}

There are limited differences in the predictive ability of the more parsimonious distributions compared with GB2, confirming previous evidence that a flexible distribution is not a substitute for finding the correct distribution (Jones et al., [2014](#hec3787-bib-0005){ref-type="ref"}). GB2 performs reasonably well at predicting tail probabilities, although there are some disparities at the very high fibrinogen levels (90th quantile) and HbA1c above the pre‐diabetes threshold (HbA1c ≥ 42).

5. CONCLUSION {#hec3787-sec-0006}
=============

We illustrate the comparative performance of a set of more flexible parametric distributions: the GB2, GG, and their nested and limiting cases for a set of biomarkers. Although some of the three‐parameter distributions nested within the GB2 (mainly the B2 and SM) outperform the latter in most of the biomarkers considered, GB2 can be used as a guide for choosing among competing distributions; a potentially useful message for applied researchers given that different biomarkers follow different distributions. The linear models estimated by OLS are dominated by almost all the competitive models. GB2 performs well at predicting biomarkers\' tail probabilities, although with some disparities at the very high levels of fibrinogen and HbA1c.

CONFLICT OF INTEREST {#hec3787-sec-0008}
====================

None.

Understanding Society is an initiative funded by the Economic and Social Research Council and various Government Departments, with scientific leadership by the Institute for Social and Economic Research, University of Essex, and survey delivery by NatCen Social Research and Kantar Public. The research data are distributed by the UK Data Service. We are grateful to the Economic and Social Research Council for financial support for this research via project "How can biomarkers and genetics improve our understanding of society and health?" (award ES/M008592/1). Andrew Jones acknowledges funding from the Leverhulme Trust Major Research Fellowship (MRF‐2016‐004). The funders, data creators, and UK Data Service have no responsibility for the contents of this paper.

 {#hec3787-sec-0009}

![Quantile--quantile plots of the biomarkers by gender \[Colour figure can be viewed at <http://wileyonlinelibrary.com>\]](HEC-27-1617-g003){#hec3787-fig-0003}

###### 

Descriptive statistics

  Biomarker           Mean    Median   Standard deviation   Skewness   Kurtosis   Minimum   Maximum   Sample size
  ------------------- ------- -------- -------------------- ---------- ---------- --------- --------- -------------
  Fibrinogen (g/L)    2.79    2.70     0.59                 0.47       3.82       0.40      5.50      12,811
  HbA1c (mmol/mol)    37.25   36.00    8.19                 4.17       31.15      12        133.0     12,153
  Cholesterol ratio   3.74    3.46     1.36                 1.42       6.43       1.16      13.67     12,865
  DHEAS (μmol/L)      4.62    3.80     3.24                 1.29       5.11       0.20      25.30     12,809

*Note*. DHEAS: dehydroepiandrosterone sulfate; HbA1c: glycated hemoglobin.

###### 

Estimated parameters from the GB2 and the GG models

  Biomarker           GB2                         GG                                                                                
  ------------------- --------------------------- --------------------------- ------------------------- --------------------------- ---------------------------
                                                                                                                                    Ln(σ)
  Fibrinogen          7.892 \[7.017, 8.767\]      1.104 \[0.933, 1.275\]      1.299 \[1.063, 1.535\]    0.267 \[0.209, 0.326\]      −1.606 \[−1.621, −1.592\]
  HbA1c               42.986 \[36.674, 49.298\]   0.348 \[0.287, 0.410\]      0.198 \[0.167, 0.230\]    −0.461 \[−0.555, −0.368\]   −1.970 \[−2.017, −1.924\]
  Cholesterol ratio   1.442 \[0.777, 2.108\]      23.345 \[−9.920, 56.612\]   6.611 \[1.761, 11.463\]   −0.246 \[−0.290, −0.200\]   −1.169 \[−1.183, −1.157\]
  DHEAS               2.538 \[2.202, 2.873\]      1.036 \[0.846, 1.225\]      2.316 \[1.717, 2.915\]    0.446 \[0.396, 0.495\]      −0.615 \[−0.631, −0.599\]

*Note*. DHEAS: dehydroepiandrosterone sulfate; GB2: generalized beta of the second kind; GG: generalized gamma; HbA1c: glycated hemoglobin.

[^1]: The limited number of covariates may also alleviate concerns that, for less parsimonious specifications, the best specification for each model need to be compared rather than using the same covariates (Jones et al., [2014](#hec3787-bib-0005){ref-type="ref"}). However, the relative performance of our models (Table [2](#hec3787-tbl-0002){ref-type="table"}) remained the same in the case of no covariates.
